Honda R&D Co., Ltd. has entered a multi-year joint research agreement with QuantumScape (NASDAQ: QS), sending shares of the solid-state battery developer climbing sharply on the news.
The agreement follows Honda’s in-depth technical evaluation and benchmarking of QuantumScape’s QS solid-state lithium-metal battery platform and related manufacturing processes.
Shares of QuantumScape rose 13.4% following the announcement, reflecting investor enthusiasm for another major global automaker formally backing the company’s technology.
Honda’s move represents a progression from evaluation to active collaboration, though it stops short of any commercial supply commitment at this stage.
The partnership adds significant weight to QuantumScape’s validation story, positioning Honda alongside Volkswagen Group’s PowerCo as a major automotive partner exploring the platform.
QuantumScape’s earlier collaboration with PowerCo is focused on industrializing the same QSE-5 platform and Cobra manufacturing process that Honda will now jointly research.
Together, these two relationships set up near-term catalysts around whether global automakers progress from joint research into concrete licensing and manufacturing commitments.
The central investment thesis for QuantumScape remains whether solid-state lithium-metal batteries can move from laboratory results to commercial products through a capital-light licensing model before cash burn becomes a critical problem.
Analyst projections vary widely, with baseline forecasts targeting $544.5 million in revenue and $33.3 million in earnings by 2029, implying an earnings swing of approximately $468 million from the current adjusted loss of $435.1 million.
More optimistic analysts have penciled in as much as $2.6 billion in revenue and around $158 million in earnings by 2029, a scenario that leans heavily on rapid Eagle Line validation and deep partner adoption across multiple automakers.
Honda’s new research agreement could lend credibility to that bullish outlook, though it equally highlights how ambitious those forecasts already are relative to the company’s current pre-revenue status.
Investors continue to weigh the appeal of growing partner validation against the ongoing reality of adjusted EBITDA losses and heavy research and development spending with no near-term licensing revenue yet confirmed.
The key near-term milestone for QuantumScape remains converting its pilot programs and early billings into clear, recurring licensing revenue that would give its capital-light development model real financial substance.
